Medexus Pharmaceuticals

MEDXF

Drug Manufacturers - Specialty & Generic · Healthcare

Exchange

Other OTC

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Good

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Medexus Pharmaceuticals is a small specialty pharmaceutical company that sells prescription drugs in Canada and the United States. Its key products include Rasuvo (a methotrexate auto-injector for rheumatoid arthritis and other conditions), Gleolan (a drug used during brain tumor surgery to help surgeons see cancer cells), and Treosulfan (used in bone marrow transplant preparation). Its main customers are hospitals, clinics, and specialty pharmacies serving patients with serious diseases.

Medexus earns revenue by selling these branded specialty drugs directly to healthcare providers and through distribution partners. The company operates primarily in North America and generates roughly $100 million or less in annual revenue, making it a micro-cap player in a competitive field. Its moat comes from holding exclusive rights to niche drugs with limited competition, but its small size means it depends heavily on a handful of products — losing market share or facing generic competition in any one of them could meaningfully hurt its financial results.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-0.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-314.1% YoY

YoY Growth Rate

Earnings declining

Insider Activity

8.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 months

$7M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Medexus Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

55.4%

Premium pricing power — 55.4% gross margin

Profit after running costs

Operating Margin

7.4%

Modest — 7.4% operating margin

Return on the money invested

ROCE

9.5%

Below par — 9.5% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-2.9%

Shrinking sales (-2.9% YoY)

Profit growth

EPS YoY

-338.7%

Earnings shrinking (-338.7% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-1.2%

Burning cash (-1.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.55

Conservative — low debt load (0.55)

Covers its interest

Interest Cover

1.66x

Dangerous — barely covers interest (1.7x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial